摘要
背景:尽管炎症性肠病(IBD)疾病过程的预测因子不准确,但我们在客观证明存在活动性疾病,并发症或对治疗干预的反应不足之后,采用反应性方法调整治疗方案。在这种情况下,适当的监测对于及时做出管理决策至关重要。 目的:回顾临床评估,生物标志物,放射学和内镜在监测IBD患者中的作用。 结果:评估临床症状是IBD监测的基石;在溃疡性结肠炎(UC)中粘膜病变与症状存在之间存在可接受的对应关系,但是在克罗恩病(CD)中,这两者之间存在相当大的断开,并且监测需要补充测试。 越来越多地使用血液和粪便标志物,如C-反应蛋白和粪便钙卫蛋白。然而,根据疾病类型(UC对CD),年龄(小儿或成人)和疾病位置(小肠对结肠疾病),这些生物标志物的操作特性是不同的。 横截面成像与内镜检查在检查CD中的炎症方面具有相似的准确性,并且对于检测狭窄和穿透性并发症具有更高的准确性。还显示磁共振成像对于测量对治疗干预的反应是准确的。 结论:横断面成像是CD患者首选的监测方法之一。内镜检查仍然是评估UC的首选检查方法,对于CD症状改变或生物标志物改变和交叉感染的患者截面成像是负面的
关键词: 生物标志物,克罗恩病,内窥镜检查,影像学,磁共振成像,溃疡性结肠炎,超声波检查。
图形摘要
Current Drug Targets
Title:Can we Monitor a Patient with Inflammatory Bowel Disease and Adapt Treatment without Endoscopy?
Volume: 19 Issue: 7
关键词: 生物标志物,克罗恩病,内窥镜检查,影像学,磁共振成像,溃疡性结肠炎,超声波检查。
摘要: Background: While predictors of disease course in inflammatory bowel diseases (IBD) are not accurate, we adapt therapies reactively, after objective demonstration of the presence of active disease, complications, or an inadequate response to a therapeutic intervention. In this context, adequate monitoring is essential to make timely management decisions.
Objective: To review the role of clinical assessment, biomarkers, radiology and endoscopy in monitoring patients with IBD.
Results: Assessment of clinical symptoms is the cornerstone of monitoring in IBD; in ulcerative colitis (UC) there is acceptable correspondence between mucosal lesions and presence of symptoms, but in Crohn's disease (CD) there is a considerable disconnection between these two, and monitoring requires complementary tests.
Blood and stool markers such as C-reactive protein and fecal calprotectin are increasingly used. However, the operating properties of these biomarkers are different according to disease type (UC vs. CD), age (pediatric or adult), and disease location (small bowel vs. colonic disease).
Cross-sectional imaging has a similar accuracy to endoscopy to detect inflammation in CD, and a higher accuracy to detect stenosing and penetrating complications. It has also been shown that magnetic resonance imaging is accurate for measuring response to therapeutic interventions.
Conclusion: Cross-sectional imaging is one of the preferred monitoring options in patients with CD. Endoscopy continues to be the preferred examination for assessing UC, and should still be considered in patients with CD who have symptoms or altered biomarkers and cross-sectional imaging is negative.
Export Options
About this article
Cite this article as:
Can we Monitor a Patient with Inflammatory Bowel Disease and Adapt Treatment without Endoscopy?, Current Drug Targets 2018; 19 (7) . https://dx.doi.org/10.2174/1389450117666160401125642
DOI https://dx.doi.org/10.2174/1389450117666160401125642 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers